The 29 references in paper S. Pavlishcuk A., A. Romash V., С. Павлищук А., А. Ромаш В. (2015) “Сравнительная эффективность антиагрегантной терапии нарушений тромбоцитарного гемостаза при сахарном диабете второго типа // Comparative effectiveness of antiplatelet therapy of hemostatic disorders in diabetes of the second type” / spz:neicon:ksma:y:2015:i:4:p:97-101

1
Аметов А. С. Сахарный диабет 2-го типа. Проблемы и решения. – М.: ГЭОТАР-Медиа, 2013. – 1031 с.
(check this in PDF content)
2
Голухова Е. З, Рябинина М. Н. Современные аспекты антиагрегантной терапии // Креативная кардиология. – 2013. – No 1. – С. 48–51.
(check this in PDF content)
3
Дедов И. И., Шестакова М. В. Сахарный диабет, острые и хронические заболевания // МИА. – Москва, 2011. – С. 477.
(check this in PDF content)
4
Лишневская В. Ю., Калмыков М. П. Прогностическая значимость агрегационной активности тромбоцитов для определения продолжительности предстоящей жизни больных ИБС пожилого и старческого возраста // Проблемы старения и долголетия. – 2006. – Т. 15. No 4. – С. 351–357. 101
(check this in PDF content)
5
Павлищук С. А., Никольская Л. Ф., Петрик Г. Г. Взаимоотношение агрегационной активности тромбоцитов и некоторых параметров метаболизма у здоровых людей // Физиология человека. – 2003. – No 1. – С. 136–138.
(check this in PDF content)
6
Петрик Г. Г., Павлищук С. А., Бутаева С. В. Параметры метаболизма и гемостаза при СД 1-го и 2-го типов в зависимости от компенсации углеводного обмена // Кубанский научный медицинский вестник – 2011. – No 5. – С. 118–124.
(check this in PDF content)
7
Петрик Г. Г., Павлищук С. А. Показатели метаболизма и гемостаза у больных СД 2-го типа с различной выраженностью ангиопатий // Проблемы эндокринологии – 2010. – Т. 56. No 2. – С. 15–19.
(check this in PDF content)
8
Antman E. M., Wiviott S. D., Murphy S. A. et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention. a TRITOnTIMI 38 (TRial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction) analysis // J. am. col. cardiol. – 2008. – May 27. No 51. – Р. 2028–2033.
(check this in PDF content)
9
elch J., MacCuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPaDaD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease // bMJ. – 2008. – No 337. – Р. 1840.
(check this in PDF content)
10
Berger P. B., Bhatt D. L., Fuster V. et al. bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (ChaRISMa) trial // Circulation. – 2010. – 15 Jun. No 121 (23). – Р. 2575–2583.
(check this in PDF content)
11
CaPRIE steering committee. a randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CaPRIE) // Lancet. – 1996. – Vol. 348. – P. 1329–1339.
(check this in PDF content)
12
Carr M. E. Diabetes mellitus: a hypercoagulable state // J. diabetes complications. – 2001. – V. 15. – P. 44–54.
(check this in PDF content)
13
Diener H. C. et al. aspirin and clopidogrel compared with clopidogrel alone after ischaemic stroke or transient ischaemic attack in high-risk patients (MaTCh): randomized, double-blind, placebo-controlled trial // Lancet 2004. – No 34. – Р. 331–337.
(check this in PDF content)
14
Gurbel P. A., Tantry U. S. Platelet function testing and genotyping improve outcome in patients treated with antithrom- botic agents // Circulation. – 2012. – No 125. – Р. 1276–1287.
(check this in PDF content)
15
IDF Diabetes atlas 6th edition. 2014. available from: http:// www. diabetesatlas. org].
(check this in PDF content)
16
Helgason C. M., Bolin K. M., Hoff J. A., Winkler S. R., Mangat A., Tortorice K. L., Brace L. D. Development of aspirin resistance in persons with previous stroke // Stroke. – 1994. – No 25. – Р. 2331–2336.
(check this in PDF content)
17
James S. K., Pieper K. S., Cannon C. P., et al. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials // Stroke. – 2013. – Р. 44–60.
(check this in PDF content)
18
uutilainen, A. Type 2 diabetes as a coronary heart disease equivalent. an 18-year prospective population-based study in finnish subjects // Diabetes care. – 2005. – V. 28. – P. 2901–2907.
(check this in PDF content)
19
Krasopoulos G., Brister S. J., Beattie W. S. et al. aspirin «resistance» and risk of cardiovascular morbidity: systematic review and meta-analysis // bMJ. – 2008. – January 26. No 336. – Р. 195–198.
(check this in PDF content)
20
Lincoff A. M., Bittl J. A., Harrington R. A., et al. bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: Replace-2 randomized trial // JaMa. – 2003. – No 289. – Р. 853–863.
(check this in PDF content)
21
Massie B. M., Collins J. F., Ammon S. E. et al. for the WaTCh Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure the warfarin and antiplatelet therapy in chronic heart failure (WaTCh) trial // Circulation. – 2009. – March 31. No 119. – Р. 1616–1624.
(check this in PDF content)
22
Mehta S. R., Yusuf S., Peters R. J. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary interve- ntion: the PCI-CURE study // Lancet. – 2001. – No 358. – Р. 527–533.
(check this in PDF content)
23
Montalescot G., Sideris G., Cohen R. et al. Prasugrel compared with high-dose clopidogrel in acut coronary syndrome. The randomised, doble-blind aCaPULCO study // Thromb haemost. – 2010. – No 103. – Р. 213–223.
(check this in PDF content)
24
Patrono C., Coller B., FitzGerald G. A. et al. Plateletactive drugs: The relationships among dose, effective-ness, and side effects. The seventh accp conference of antithrombotic and thrombolytic therapy // Chest. – 2004. – Vol. 126. – 234–264.
(check this in PDF content)
25
Steinhubl S. R., Berger P. B., Mann J. T. et al., for the CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. a. randomized controlled trial // JaMa. – 2002. – No 288. – Р. 2411–2420.
(check this in PDF content)
26
U. S. Public health service. Treating tobacco use and dependence: summary. – Rockville, MD: U. S. public health service, June 2000. http://www. surgeon-general. gov/tobacco/.
(check this in PDF content)
27
Wallentin L., Varenhorst C., James S. et al. Prasugrel achieves greater and faster P2y12 receptor-mediated platelet inhibition than clopi-dogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease // Eur. heart. j. – 2008. – No 29. – Р. 21–30.
(check this in PDF content)
28
Wallentin L., Becker R. C., Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes // n. engl. j. med. – 2009. – september 10. No 361 (11). – Р. 1045.
(check this in PDF content)
29
Wenaweser P., Tsuchida K., Vaina S. et al. Late stent thrombosis following drug-eluting stent implantation: data from a large, twoinstitutional cohort study // World congress of cardiology barcelona, september 2–5 // Eur. heart j. – 2006. – Vol. 27 (suppl 1). – P. 154.
(check this in PDF content)